Scorpius Holdings, Inc. Announces Pricing of Public Offering
March 08 2024 - 12:20AM
Scorpius Holdings, Inc. (NYSE American: SCPX), (“Scorpius” or the
“Company”), an integrated contract development and manufacturing
organization (CDMO), today announced the pricing of its
underwritten public offering of 10,000,000 shares of its common
stock at a public offering price of $0.15 per share, for aggregate
gross proceeds of $1,500,000, before deducting underwriting
discounts, commissions and offering expenses. All of the shares of
common stock were offered by the Company. The offering is expected
to close on March 12, 2024, subject to satisfaction of customary
closing conditions.
The Company intends to use the net proceeds from
the offering primarily for working capital and general corporate
purposes.
ThinkEquity is acting as sole book-running
manager for the offering.
The securities were offered and sold pursuant to
a shelf registration statement on Form S-3 (File No. 333-251255),
including a base prospectus, filed with the U.S. Securities and
Exchange Commission (the “SEC”) on December 10, 2020 and declared
effective on December 22, 2020. The offering was made only by means
of a written prospectus. A preliminary prospectus supplement and
the accompanying base prospectus describing the terms of the
offering was filed with the SEC on its website at www.sec.gov. A
final prospectus supplement and the accompanying base prospectus
describing the terms of the offering will be filed with the SEC on
its website at www.sec.gov. Copies of the preliminary prospectus
supplement and final prospectus supplement and the accompanying
prospectus relating to the offering may also be obtained, when
available, from the offices of ThinkEquity, 17 State Street, 41st
Floor, New York, New York 10004.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be
any sale of these securities in any state or jurisdiction in which
such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Scorpius Holdings,
Inc.
Scorpius Holdings Inc. is an integrated large
molecule contract development and manufacturing organization (CDMO)
focused on rapidly advancing biologic and cell therapy programs to
the clinic and beyond. Scorpius offers a broad array of analytical
testing, process development, and manufacturing services to
pharmaceutical and biotech companies at its state-of-the-art
facilities in San Antonio, TX. With an experienced team and new,
purpose-built U.S. facilities, Scorpius is dedicated to transparent
collaboration and flexible, high-quality biologics
biomanufacturing. For more information, please visit
www.scorpiusbiologics.com.
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. In
some cases forward-looking statements can be identified by
terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions and include statements
regarding the timing and completion of the proposed offering.
Important factors that could cause actual results to differ
materially from current expectations include, among others, the
timing of closing of the offering, and other factors described in
the Company’s annual report on Form 10-K for the year ended
December 31, 2022, subsequent quarterly reports on Form 10-Qs and
any other filings the Company makes with the SEC. The information
in this presentation is provided only as of the date presented, and
the Company undertakes no obligation to update any forward-looking
statements contained in this press release on account of new
information, future events, or otherwise, except as required by
law.
For Investor Relations Inquiries:
David Waldman
+1 919 289 4017
investorrelations@nighthawkbio.com
Nighthawk Biosciences (AMEX:NHWK)
Historical Stock Chart
From Apr 2024 to May 2024
Nighthawk Biosciences (AMEX:NHWK)
Historical Stock Chart
From May 2023 to May 2024